Medical Research Group of Egypt, Cairo, Egypt.
Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
Ir J Med Sci. 2024 Jun;193(3):1621-1639. doi: 10.1007/s11845-023-03602-4. Epub 2024 Jan 17.
This systematic review and network meta-analysis aimed to evaluate the three different administration routes of vitamin B12: oral, intramuscular (IM), and sublingual (SL) routes.
We searched four electronic databases (PubMed, Scopus, Web of Science, and Cochrane CENTRAL Register of Controlled Trials). We included only comparative studies. We performed a frequentist network meta-analysis to measure network estimates for the relative outcomes. Moreover, we conducted a pairwise meta-analysis using a random effect model to obtain direct estimates for outcomes. All outcomes were continuous, and the relative treatment effects were pooled as mean difference (MD) with 95% confidence intervals.
Thirteen studies were included in the meta-analysis, with a total of 4275 patients. Regarding increasing vitamin B12 levels, the IM route ranked first, followed by the SL route (MD = 94.09 and 43.31 pg/mL, respectively) compared to the oral route. However, these differences did not reach statistical significance owing to the limited number of studies. Regarding the hemoglobin level, the pooled effect sizes showed no difference between all routes of administration that could reach statistical significance. However, the top two ranked administration routes were the oral route (78.3) and the IM route (49.6).
All IM, oral, and SL routes of administration of vitamin B12 can effectively increase the level of vitamin B12 without significant differences between them, as thought previously. However, the IM route was the top-ranked statistically but without clinical significance. We found no significant difference among studied administrated routes in all other CBC parameters and homocysteine levels.
本系统评价和网络荟萃分析旨在评估维生素 B12 的三种不同给药途径:口服、肌内(IM)和舌下(SL)途径。
我们检索了四个电子数据库(PubMed、Scopus、Web of Science 和 Cochrane 对照试验中心注册库)。我们只纳入了比较研究。我们进行了频率主义网络荟萃分析,以衡量相对结局的网络估计值。此外,我们使用随机效应模型进行了成对荟萃分析,以获得结局的直接估计值。所有结局均为连续变量,相对治疗效果以均数差值(MD)和 95%置信区间(CI)进行汇总。
共纳入 13 项研究,总计 4275 例患者。在提高维生素 B12 水平方面,IM 途径排名第一,其次是 SL 途径(MD 分别为 94.09 和 43.31 pg/mL),优于口服途径。然而,由于研究数量有限,这些差异没有达到统计学意义。在血红蛋白水平方面,所有给药途径的汇总效应大小均无差异,无法达到统计学意义。然而,排名前两位的给药途径是口服途径(78.3)和 IM 途径(49.6)。
所有 IM、口服和 SL 途径的维生素 B12 给药均可有效提高维生素 B12 水平,且彼此之间无显著差异,这与之前的观点一致。然而,从统计学角度来看,IM 途径是排名最高的,但没有临床意义。我们在所有其他 CBC 参数和同型半胱氨酸水平方面未发现研究中给药途径之间存在显著差异。